Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aldara vs Solaraze in Actinic Keratosis (LEIDA)
NCT00777127Phase 4Completed
- Sponsor
- Meda
- Start
- Dec 2008
- Primary completion
- Nov 2012
- Modality
- Nucleic Acid-Directed Small Molecules, Irreversible Covalent Inhibitors, Metabolically Activated Prodrugs
- Countries
- 3
01
Overview
Phase 4, randomised, open-label trial of imiquimod in actinic keratosis (AK) (2 arms), sponsored by Meda. Primary endpoint: Recurrence in the study treatment area at month 12. Started Dec 2008; status: completed.
02
Drugs
imiquimod
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on NCT00777127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00777127.